Transcenta Holding Limited — Board/Management Information 2021

Dec 17, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [138 x 40] intentionally omitted <==

Transcenta Holding Limited 創勝集團醫藥有限公司

(registered by way of continuation in the Cayman Islands with limited liability)

(Stock Code: 6628)

APPOINTMENT OF CHIEF FINANCIAL OFFICER

The board of directors (the “ Board ”) of Transcenta Holding Limited (the “ Company ”) is pleased to announce that Mr. Xiaolu Weng (“ Mr. Weng ”) has been appointed as the chief financial officer of the Company with effect from the date of this announcement.

The biographical details of Mr. Weng are set out below:

Prior to joining the Company, Mr. Weng served as the vice president and head of finance at CStone Pharmaceuticals, a company listed on The Stock Exchange (the “ Stock Exchange ”) of Hong Kong Limited (stock code: 02616), and had the overall responsibilities for financial functions. Prior to that, Mr. Weng consecutively served as the vice president and head of finance at Everest Medicines Limited, a company listed on the Stock Exchange (stock code: 01952), and the chief financial officer of China at Amgen. Mr. Weng holds a master’s degree in finance and accounting from the University of Sydney, Australia. He is a certified public accountant in Australia and a member of the Association of Chartered Certified Accountants.

The Board would like to take this opportunity to welcome Mr. Weng in joining the Company.

By Order of the Board Transcenta Holding Limited Xueming Qian Executive Director and Chief Executive Officer

Hong Kong, December 17, 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Xueming Qian as executive Director and chief executive officer, Dr. Michael Ming Shi and Mr. Albert Da Zhu as executive Directors, Dr. Yining (Jonathan) Zhao as chairman and non-executive Director, and Mr. Jiasong Tang, Dr. Jun Bao and Mr. Zhihua Zhang as independent non-executive Directors.